OBJECTIVES: Parkinson’s disease (PD) is a neurodegenerative disorder causing progressive motor impairment and disability. The effects of PD are measure throughout the Unified Parkinson’s Disease Rating Scale (UPDRS). PD treatments include drugs that increase the functional ability of the underactive dopaminergic system or that reduce the excessive influence of excitatory cholinergic neurons. The purpose of this study was to conduct an indirect comparison of the efficacy of different alternatives of early treatment for Parkinson’s disease regarding the UPDRS. METHODS: We realized a systematic literature review in eigth data base with keys word: Parkinson disease, early treatment, levodopa, pramipexole, rasagiline, selegiline and placebo. The inclusion criteria were patients with parkinson’s disease in Hoehn and Yahr I, 2 or 3, UPDRS scale,  lenguaje spanish and english, since January 1994 to May 2014. Results of all trials were analyzed simultaneously with a Bayesian Mixed Treatment Comparison (MTC) to obtain the relative efficacy into the treatments. RESULTS: There were 1080 clinical trials (CT), only five meeting the inclusion criteria: levodopa (1CT), pramipexole (1 CT), rasagiline (2CT) and selegiline (1CT), using a random model levodopa showed the best punctuation in UPDRS (probability=0.61) when all the treatments were compared. Also, it showed a mean difference of 7 relative to placebo, CrI (0.14-14); 2.2 relative to pramipexole CrI (-7.5- 12); 3.5 relative to rasagiline, CrI (-4.8-12) and 1.6 relative to selegiline, CrI (-8.3-12). CONCLUSIONS: Findings of this study indicate that Levodopa provides a greater disability and impairment reduction in patients with Parkinson disease (measured by UPDRS) patients than pramipexole, rasagiline and selegiline as first treatment option to early parkinson’s disease in monotherapy.